Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
INO's Cash-to-Debt is ranked higher than
96% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. INO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
INO' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.17  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.71
INO's Equity-to-Asset is ranked higher than
56% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INO: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
INO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.49  Med: 0.78 Max: 0.93
Current: 0.71
0.49
0.93
Interest Coverage No Debt
INO's Interest Coverage is ranked higher than
96% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
INO' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 1.71
Beneish M-Score: -1.75
WACC vs ROIC
13.55%
-343.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -215.55
INO's Operating Margin % is ranked lower than
61% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. INO: -215.55 )
Ranked among companies with meaningful Operating Margin % only.
INO' s Operating Margin % Range Over the Past 10 Years
Min: -651  Med: -266.85 Max: -84.5
Current: -215.55
-651
-84.5
Net Margin % -208.49
INO's Net Margin % is ranked lower than
61% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. INO: -208.49 )
Ranked among companies with meaningful Net Margin % only.
INO' s Net Margin % Range Over the Past 10 Years
Min: -618.02  Med: -277.15 Max: -71.94
Current: -208.49
-618.02
-71.94
ROE % -47.34
INO's ROE % is ranked lower than
58% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. INO: -47.34 )
Ranked among companies with meaningful ROE % only.
INO' s ROE % Range Over the Past 10 Years
Min: -152.12  Med: -46.91 Max: -20.35
Current: -47.34
-152.12
-20.35
ROA % -36.97
INO's ROA % is ranked lower than
56% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. INO: -36.97 )
Ranked among companies with meaningful ROA % only.
INO' s ROA % Range Over the Past 10 Years
Min: -98.97  Med: -32.88 Max: -16.89
Current: -36.97
-98.97
-16.89
ROC (Joel Greenblatt) % -898.65
INO's ROC (Joel Greenblatt) % is ranked lower than
60% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. INO: -898.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7552.88  Med: -3809.2 Max: -576.69
Current: -898.65
-7552.88
-576.69
3-Year Revenue Growth Rate 18.30
INO's 3-Year Revenue Growth Rate is ranked higher than
69% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. INO: 18.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -81.2  Med: 3.5 Max: 163.7
Current: 18.3
-81.2
163.7
3-Year EBITDA Growth Rate 38.10
INO's 3-Year EBITDA Growth Rate is ranked higher than
85% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. INO: 38.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
INO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34.1  Med: -16.6 Max: 38.1
Current: 38.1
-34.1
38.1
3-Year EPS without NRI Growth Rate -10.90
INO's 3-Year EPS without NRI Growth Rate is ranked lower than
61% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. INO: -10.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
INO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -28.2  Med: -10.5 Max: 27.9
Current: -10.9
-28.2
27.9
GuruFocus has detected 4 Warning Signs with Inovio Pharmaceuticals Inc $INO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INO's 10-Y Financials

Financials (Next Earnings Date: 2017-06-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

INO Guru Trades in Q4 2015

Jim Simons 392,781 sh (New)
Joel Greenblatt 37,123 sh (New)
Paul Tudor Jones Sold Out
» More
Q1 2016

INO Guru Trades in Q1 2016

Paul Tudor Jones 50,305 sh (New)
Jim Simons Sold Out
Joel Greenblatt Sold Out
» More
Q2 2016

INO Guru Trades in Q2 2016

Paul Tudor Jones 26,801 sh (-46.72%)
» More
Q3 2016

INO Guru Trades in Q3 2016

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:PRTK, NAS:CERS, OTCPK:SNBIF, NAS:ADAP, NAS:MCRB, NAS:RARX, OTCPK:SPHDF, NAS:CLDX, NAS:ASMB, NAS:CRVS, NAS:BYSI, NAS:NSTG, NAS:CARA, NAS:RETA, NAS:NTLA, OTCPK:ABVC, NAS:CRBP, NAS:MYOK, NAS:SPPI, NAS:CALA » details
Traded in other countries:GBMB.Germany,
Headquarter Location:USA
Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.

Inovio Pharmaceuticals is a biotechnology company that develops active DNA immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies. Inovio aims to advance products through to commercialization. The company uses acquisitions, strategic alliances, and licensing agreements to fund the development of its products.

Top Ranked Articles about Inovio Pharmaceuticals Inc

Inovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Expanded Clinical Trial
Inovio and Collaborators Receive NIH Grant to Evaluate HIV Immunotherapy PENNVAX®-GP’s Ability to Induce Remission of HIV Infection and End Lifetime of Drug Therapy

Grant will fund therapeutic clinical studies testing PENNVAX-GP with INO-9012 (an IL-12 immune activator) alone and with the addition of a PD-1 checkpoint inhibitor

PLYMOUTH MEETING, Pa., March 30, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its academic and industry collaborators received a multi-year $6.95 million grant from the NIH’s National Institute of Allergy and Infectious Diseases to develop a single or combination therapy using Inovio’s PENNVAX-GP with the goal of attaining long-term HIV remission in the absence of antiviral drugs.
Although current antiretroviral therapy can reduce the amount of circulating HIV in the blood to an undetectable level, latent cellular reservoirs of HIV continue to exist in the body such that when therapy is discontinued, these cells begin to produce HIV again. This proof-of-concept clinical program will test whether enhancing anti-HIV specific CD8 killer T cell immune responses alone or in combination with other products can influence the size of the viral reservoir pool, potentially resulting in reducing or eradicating the virus. This is a two-step clinical study in HIV-positive subjects to assess Inovio’s HIV immunotherapy PENNVAX-GP with INO-9012 (an IL-12 immune activator) alone and with the addition of a PD-1 checkpoint inhibitor. All trials will be randomized, double-blind, placebo-controlled assessments of PENNVAX-GP. They will be conducted at the University of California in San Francisco and Los Angeles. PD-1 checkpoint inhibitors have proven effective in treating cancer and may have a role in the management of chronic infectious diseases. This trial seeks to demonstrate that an in vivo immunotherapy combining a PD-1 inhibitor and PENNVAX-GP will enhance the CD8 killer T cell response to HIV infected cells. Development of Inovio’s PENNVAX-GP immunotherapy, which widely targets multiple major clades of HIV — providing global coverage — has been funded through a $25 million NIAID contract awarded to Inovio and its collaborators. In addition, Inovio and its collaborators were awarded a five-year $16 million Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant in 2015 from NIAID. PENNVAX-GP is currently being studied in a phase I trial (HVTN-098) to evaluate safety and immunogenicity in 94 healthy volunteers. In this study, PENNVAX-GP is being evaluated as a preventive vaccine. The newly funded study will assess the impact of this vaccine approach in a therapeutic setting. Steven G. Deeks, MD, the grant and clinical trial’s Principal Investigator, and Professor of Medicine in Residence at the University of California, San Francisco, said, “There is growing recognition that we will need to generate powerful CD8 T cells that target vulnerable regions of the virus and which can migrate to the tissues where the virus hides. The preliminary data from other Inovio-sponsored studies makes me enthusiastic that this vaccine might fill an important niche in future curative strategies.” Dr. J. Joseph Kim, Inovio's President and CEO, said, "We are thrilled to receive this NIH funding to test the combination of Inovio’s HIV immunotherapy with a PD-1 inhibitor. Similar to what we are doing in the cancer field with INO-3112 and INO-5401, we believe that the one-two punch of generating potent killer T cells with our immunotherapies combined with PD-1/PDL-1 checkpoint therapies could be an important step in generating functional cure for these diseases.”      About HIV Infection Nearly 36 million people have died from HIV-related causes and 35 million are living with HIV. HIV is a retrovirus that causes acquired immunodeficiency syndrome (AIDS), a condition in which progressive failure of the immune system all­­ows life-threatening opportunistic infections and cancers to thrive. HIV is classified into clades, sub-types within which the virus has genetic similarities. The most prevalent clades are B (found mainly in North America and Europe), A and D (found mainly in Africa), and C (found mainly in Africa and Asia). HIV clade C accounts for 48% of worldwide and 51% of African-HIV type 1 cases. It is the most rapidly spreading subtype of HIV. Although a highly active antiretroviral therapy regimen has dramatically transformed the treatment of the disease in developed countries, effective HIV vaccines are needed to stop the spread of disease and reduce the need for antiretroviral treatments, which can have harsh side effects and lose their efficacy over time. About Inovio's PENNVAX® HIV Vaccines and Immunotherapies Inovio completed initial clinical studies of its HIV immunotherapy PENNVAX-B, targeting clade B viruses, to achieve proof of principle in generating potent immune responses using its SynCon® immunotherapy technology. In two published phase 1 studies, PENNVAX-B immunization generated high levels of activated, antigen-specific CD8 killer T cells with proper functional characteristics. This ability uniquely positions PENNVAX as an important product candidate for both preventing and treating HIV infections. Using a $25 million contract from the NIH, Inovio designed its universal, multi-clade, multi-antigen PENNVAX-GP immunotherapy targeting the env, gag and pol antigens to provide coverage against all major HIV-1 clades. PENNVAX-GP is Inovio's lead preventive and therapeutic immunotherapy for HIV. About Inovio Pharmaceuticals, Inc. Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit www.inovio.com. This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, including the HIV immunotherapy PENNVAX-GP, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, [email protected]
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, [email protected]

Read more...
George Bickerstaff Elected to Inovio’s Board of Directors

Former Novartis CFO brings finance, fundraising and M&A experience to Inovio

PLYMOUTH MEETING, Pa., March 21, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today the election of George Bickerstaff to its Board of Directors. 
Mr. Bickerstaff is an internationally recognized expert in finance, healthcare and information technology.  He has served Novartis Pharma AG as its chief financial officer and held senior financial positions at IMS Health, Dun & Bradstreet and General Electric. He serves on numerous boards and is currently partner and managing director of M.M. Dillon & Co., an investment bank and financial advisory firm. Dr. J. Joseph Kim, Inovio's President and CEO, said, "George Bickerstaff’s finance, operations and international business experience will be an asset to Inovio as we advance our products to commercialization and enter collaborative arrangements with other companies. The addition of George to our Board helps ensure that Inovio will continue to benefit from a deep and wide range of experience.” About Inovio Pharmaceuticals, Inc. Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit www.inovio.com. This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, [email protected]
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, [email protected]

Read more...
Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2016 Financial Results on March 15, 2017

PLYMOUTH MEETING, Pa., March 09, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to discuss its 2016 fourth quarter and year end financial results and provide a corporate update on Wednesday, March 15, 2017 at 4:30 p.m. ET.
A live and archived version of the audio presentation will be available online at http://www.investorcalendar.com/IC/CEPage.asp?ID=175658 as well as through the "Webcast" tab on Inovio's home page at www.inovio.com. This is a listen-only event but will include a live Q&A with analysts. A replay of the conference call will be accessible two hours after the call at 877-481-4010 (domestic) or 919-882-2331 (international) using passcode 10254. About Inovio Pharmaceuticals, Inc. Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit www.inovio.com. This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2015, our Form 10-Q for the quarter ended September 30, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
CONTACTS:                                                                                                                           
Investors:          Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, [email protected]
Media:              Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, [email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 3.77
INO's PB Ratio is ranked lower than
53% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. INO: 3.77 )
Ranked among companies with meaningful PB Ratio only.
INO' s PB Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.66 Max: 13.19
Current: 3.77
0.38
13.19
PS Ratio 12.98
INO's PS Ratio is ranked lower than
53% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. INO: 12.98 )
Ranked among companies with meaningful PS Ratio only.
INO' s PS Ratio Range Over the Past 10 Years
Min: 1.5  Med: 15.47 Max: 74.29
Current: 12.98
1.5
74.29
EV-to-EBIT -5.08
INO's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. INO: -5.08 )
Ranked among companies with meaningful EV-to-EBIT only.
INO' s EV-to-EBIT Range Over the Past 10 Years
Min: -30.5  Med: -5.1 Max: -0.3
Current: -5.08
-30.5
-0.3
EV-to-EBITDA -5.30
INO's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. INO: -5.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
INO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.3  Med: -5.6 Max: -0.3
Current: -5.3
-33.3
-0.3
Current Ratio 2.84
INO's Current Ratio is ranked lower than
64% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. INO: 2.84 )
Ranked among companies with meaningful Current Ratio only.
INO' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 3.56 Max: 11.87
Current: 2.84
1.04
11.87
Quick Ratio 2.84
INO's Quick Ratio is ranked lower than
60% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. INO: 2.84 )
Ranked among companies with meaningful Quick Ratio only.
INO' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 3.56 Max: 11.87
Current: 2.84
1.04
11.87
Days Sales Outstanding 163.28
INO's Days Sales Outstanding is ranked lower than
87% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. INO: 163.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
INO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.24  Med: 80.05 Max: 163.28
Current: 163.28
6.24
163.28

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.10
INO's 3-Year Average Share Buyback Ratio is ranked lower than
52% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. INO: -12.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.3  Med: -30.8 Max: -12
Current: -12.1
-45.3
-12

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.59
INO's Price-to-Net-Cash is ranked lower than
63% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. INO: 8.59 )
Ranked among companies with meaningful Price-to-Net-Cash only.
INO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.18  Med: 7.06 Max: 36.25
Current: 8.59
2.18
36.25
Price-to-Net-Current-Asset-Value 6.27
INO's Price-to-Net-Current-Asset-Value is ranked lower than
54% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. INO: 6.27 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.99  Med: 6.94 Max: 26.98
Current: 6.27
1.99
26.98
Price-to-Tangible-Book 4.42
INO's Price-to-Tangible-Book is ranked lower than
51% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. INO: 4.42 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.92  Med: 4.99 Max: 16.64
Current: 4.42
1.92
16.64
Price-to-Median-PS-Value 0.84
INO's Price-to-Median-PS-Value is ranked higher than
60% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. INO: 0.84 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28  Med: 1.07 Max: 54.05
Current: 0.84
0.28
54.05
Earnings Yield (Greenblatt) % -19.69
INO's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. INO: -19.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -23.15  Med: 0 Max: 0
Current: -19.69
-23.15
0

More Statistics

Revenue (TTM) (Mil) $35.37
EPS (TTM) $ -1.01
Beta1.89
Short Percentage of Float15.28%
52-Week Range $5.83 - 11.69
Shares Outstanding (Mil)74.32

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 27 28 55
EPS ($) -1.26 -1.30 -0.96
EPS without NRI ($) -1.26 -1.30 -0.96
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:INO

Headlines

Articles On GuruFocus.com
Inovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Expanded Apr 11 2017 
Inovio and Collaborators Receive NIH Grant to Evaluate HIV Immunotherapy PENNVAX®-GP’s Ab Mar 30 2017 
George Bickerstaff Elected to Inovio’s Board of Directors Mar 21 2017 
Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2016 Financial Results on March 15, 201 Mar 09 2017 
Inovio Pharmaceuticals' CEO Dr. J. Joseph Kim Interviewed by The Life Sciences Report Oct 30 2014 
Inovio CEO Invests in 250,000 Shares of Company Stock Aug 13 2014 
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
Weekly CFO Buys Highlight: ZBB, INO, LPR, PMC, FGP, PRMW Jun 17 2012 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 

More From Other Websites
Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers Apr 24 2017
Inovio Pharmaceuticals Stock History: From A to Zika Apr 18 2017
Inovio's Ebola Vaccine Positive in Expanded Phase I Study Apr 12 2017
This Survey's Bad News Could Be Good News for Inovio Pharmaceuticals, Inc. Apr 12 2017
Inovio Stock Rises on Positive Results From Ebola Vaccine Tests Apr 11 2017
Inovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Expanded... Apr 11 2017
Austrian biotech Themis launches Zika vaccine clinical trial Apr 11 2017
ETFs with exposure to Inovio Pharmaceuticals, Inc. : April 7, 2017 Apr 07 2017
Inovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : INO-US : March... Mar 30 2017
Inovio and Collaborators Receive NIH Grant to Evaluate HIV Immunotherapy PENNVAX®-GP’s... Mar 30 2017
ETFs with exposure to Inovio Pharmaceuticals, Inc. : March 27, 2017 Mar 27 2017
George Bickerstaff Elected to Inovio’s Board of Directors Mar 21 2017
Inovio Pharmaceuticals, Inc. :INO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Inovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : INO-US : March... Mar 17 2017
Here's What Hurt Inovio Pharmaceuticals Inc. Stock Today Mar 16 2017
Inovio (INO) Q4 Loss Wider than Expected; Shares Decline Mar 16 2017
Inovio reports 4Q loss Mar 15 2017
Inovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results Mar 15 2017
Williams-Sonoma Among 5 Earnings Plays That Could Squeeze the Shorts Mar 13 2017
4 Most Shorted Stocks Reporting Earnings This Week Mar 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)